MURANO
2018
Venetoclax + Rituximab in Relapsed/Refractory CLL
In 389 patients with relapsed or refractory chronic lymphocytic leukaemia, fixed-duration venetoclax + rituximab for two years improved progression-free survival compared with bendamustine + rituximab.
Result
Efficacy: Progression-free survivalHR 0.17
Below 1 favours fixed-duration venetoclax + rituximab for two years, above 1 favours bendamustine + rituximab.
- Absolute difference
- 48.6 points
The absolute difference is derived from the event rates.
Also reported: 4-yr OS 85.3% vs 66.8% (HR 0.41).
- Subtopic
- Relapsed/refractory CLL
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Seymour JF, et al. N Engl J Med. 2018;378(12):1107-1120; Kater AP, et al. J Clin Oncol. 2020;38(34):4042-4054.doi 10.1056/NEJMoa1713976
Discussion & critique
Established fixed-duration, MRD-driven, chemotherapy-free therapy in R/R CLL, a paradigm now extended to first-line treatment (CLL14).